1968P Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) + pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC).

Authors :: Rosenberg, J.E.
Petrylak, D.P.
Flaig, T.
Hoimes, C.J.
Gupta, S.
O'Donnell, P.H.
Mar, N.
Friedlander, T.
Tagawa, S.T.
Bilen, M.A.
Brown, J.R.
McKay, R.R.
Merchan, J.R.
Srinivas, S.
Shetty, A.
Homet Moreno, B.
Davis, G.
Wirtz, H.
Zhu, Y.
Milowsky, M.I.
Source :: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS1139-S1140. 2p.
Publication Year :: 2024

Subjects :: *TRANSITIONAL cell carcinoma
*CISPLATIN
*PEMBROLIZUMAB
*METASTASIS

Full Text Access

Tools